0000892251-19-000006.txt : 20190125 0000892251-19-000006.hdr.sgml : 20190125 20190125102600 ACCESSION NUMBER: 0000892251-19-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190124 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20190125 DATE AS OF CHANGE: 20190125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC CENTRAL INDEX KEY: 0000794172 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 310888197 STATE OF INCORPORATION: OH FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14902 FILM NUMBER: 19541490 BUSINESS ADDRESS: STREET 1: 3471 RIVER HILLS DR CITY: CINCINNATI STATE: OH ZIP: 45244 BUSINESS PHONE: 5132713700 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 FORMER COMPANY: FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 8-K 1 form8k012419.htm
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  January 24, 2019
MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio
0-14902
31-0888197
(State or other jurisdiction of incorporation)
(Commission File Number)
 
(IRS Employer Identification No. )

3471 River Hills Drive, Cincinnati, Ohio
45244
(Address of principal executive offices)
(Zip Code)
 
Registrant's telephone number, including area code (513) 271-3700
 
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2).
Emerging growth company ☐
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐


Item 5.07   Submission of Matters to a Vote of Security Holders.

The following matters were submitted to a vote of shareholders at the Company's Annual Meeting of Shareholders held on January 24, 2019:
 
(a)   Votes regarding the election of eight directors:

 Name
 For
 Withheld
Broker Non-Votes
       
 James M. Anderson
     34,273,033
     1,076,936
     4,443,913
 Dwight E. Ellingwood
     35,028,730
        321,239
     4,443,913
 Jack Kenny
     34,752,181
        597,788
     4,443,913
 John C. McIlwraith
     35,015,556
        334,413
     4,443,913
 David C. Phillips
     34,201,968
     1,148,001
     4,443,913
 John M. Rice, Jr.
     35,061,738
        288,231
     4,443,913
 Catherine A. Sazdanoff
     34,602,998
        746,971
     4,443,913
 Felicia Williams
     35,231,463
        118,506
     4,443,913

(b)   Advisory votes regarding named executive officer compensation:

For 
 Against
 Abstain
 Broker Non-Votes
34,210,282
 1,070,965
 68,722
 4,443,913
 

(c)   Votes regarding the ratification of the Audit Committee's appointment of Grant Thornton LLP as the Company's Independent Registered Public Accountants for fiscal 2019:

 For
 Against
 Abstain
38,350,159
 1,386,134
 57,589


 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MERIDIAN BIOSCIENCE, INC.
Date:  January 25, 2019
 
 
 
 
By: /s/ Eric S. Rasmussen
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)